• Shavez
• Poonam gangwar

Torsemide (known as torasemide in Europe) is a novel sulfonylurea loop diuretic approved for treating edema associated with congestive heart failure, renal dysfunction, and hepatic disease, and for hypertension, either alone or combined with other antihypertensive. As a weakly basic loop diuretic within the pyridine sulfonylurea group, torsemide is particularly effective for managing hypertension and edema related to heart failure, renal, or hepatic disorders. However, it’s limited solubility in water and bitter taste present challenges. To address these issues, torsemide was preformulated into a solid dispersion using suitable water-soluble carriers and flavoring agents, enhancing drug absorption, reducing peak plasma level fluctuations, and minimizing side effects. This method also allows the development of flexible oral dosage forms, enabling the formulation and blending of different, even incompatible, drug substances into a single dosage form. Torsemide and Amiloride Hydrochloride, both diuretic-class antihypertensive drugs, are marketed together in tablet form to treat essential hypertension and manage primary hypertension and edema associated with congestive heart failure. This research aimed to develop stability-indicating RP-HPLC methods for analyzing Torsemide and Amiloride Hydrochloride in combined dosage forms. In veterinary medicine, managing congestive heart failure (CHF) often relies on empirical methods, highlighting the need for a more quantitative approach to assess diuretic responsiveness. Understanding the relationship between diuretic measures, particularly urinary sodium excretion, and clinical outcomes is essential. Longitudinal studies are critical for refining these measures and optimizing treatment protocols. These advancements will improve CHF management in companion animals, enhancing their quality of life and prognosis. By bridging current knowledge gaps and focusing on quantitative diuretic responsiveness, both human and veterinary medicine can achieve better health outcomes through more precise and effective treatments for conditions like CHF.

Torsemide, Diuretic responsiveness, Stability-indicating RP-HPLC, Congestive heart failure (CHF). Pharmaceutical formulation

"Advancements in Torsemide Capsule Formulations: A Comprehensive Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.c531-c540, June-2024, Available :http://www.jetir.org/papers/JETIR2406267.pdf

"Advancements in Torsemide Capsule Formulations: A Comprehensive Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppc531-c540, June-2024, Available at : http://www.jetir.org/papers/JETIR2406267.pdf